First-half 2024 revenue

First-half 2024 revenue

Very dynamic business activity

  • H1 revenue: €419.2m, up 11.8% at CER1
  • A trajectory driven by all activities and geographical areas
  Solid increase in profitability
  • The restated EBITDA margin2 was 15.4%, compared to 12.7% a year earlier
  • Operating income almost tripled to €30.3m
  Upward revision of annual guidance
  • Revenue: expected growth of over 9% like-for-like and at CER (>8% previously)
  • Profitability: restated EBITDA margin rate higher than in 2021 (14.4%)

Read more
Ch Hero

Guerbet Switzerland

GUERBET has been an active presence on the Swiss radiological scene for many decades now. It all started in the early 60s, and more precisely in 1963 when the company Max Ritter Pharma began distributing GUERBET contrast media. This changed in the 80s, when the GUERBET group established a direct presence in some European countries. On July 1, 1987 the Swiss subsidiary, GUERBET AG was founded with its sales reps’ team composed of former Max Ritter Pharma employees. The first gadolinium-based contrast agent was launched shortly afterwards.

Read more

Search Min

Contact us

Scalpelday1

Pharmacovigilance